FCN-338 + azacitidine

FCN-338 + azacitidine is an investigational **combination therapy** consisting of FCN-338, a potent and highly selective small-molecule inhibitor of BCL-2, and azacitidine, a hypomethylating agent. FCN-338 directly inhibits BCL-2, blocking an anti-apoptotic protein critical for cancer cell survival, especially in hematological malignancies. Azacitidine works by inhibiting DNA methyltransferase, resulting in hypomethylation of DNA and apoptosis, promoting cytotoxic effects on abnormal hematopoietic cells. This combination is being developed primarily for treatment of **myeloid neoplasms** and relapsed/refractory acute myeloid leukemia (AML)[1][3][7][9]. FCN-338 was self-developed by Fochon Pharmaceuticals, a subsidiary of Shanghai Fosun Pharmaceutical, and is at Phase II development in combination therapy for myeloid malignancies[3][5][7][9].